Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
Colin F. Spraggs(GlaxoSmithKline (United Kingdom)), Martine Piccart(Université Libre de Bruxelles), Zeba Aziz(Rashid Latif Medical College), Julie R. Gralow(American Society of Clinical Oncology), Liling Warren, Laura R. Parham(PAREXEL International (United States)), E. Pérez(Instituto de Astrofísica de Andalucía), Shahid Ahmed(Emory University), Linda P. Briley(PAREXEL International (United States)), Georgia Demetriou(University of the Witwatersrand), Dana J. Fraser(PAREXEL International (United States)), Rocco J. Crescenzo(Pfizer (United States)), Zefei Jiang, Julie Byrne, Masakazu Toi(Mukogawa Women's University), Michael Andersson(University of Copenhagen), J. Zujewski(National Cancer Institute), L. S. Williams(Novartis (United Kingdom)), A Mehta(HCG NCHRI Cancer Centre), Nicola Jackson(Novartis (United Kingdom)), Alison Armour(AstraZeneca (United Kingdom)), Lyndsay N. Harris(National Institutes of Health)
Cited by 22
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k